From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches

Di Marzo V , Bifulco M , De Petrocellis L. The endocannabinoid system and its therapeutic exploitation . Nat Rev Drug Discov 2004; 3: 771–784 .

Perras C. Sativex for the management of multiple sclerosis symptoms . Issues Emerg Health Technol 2005; 72: 1–4 .

Baker D , Pryce G , Croxford JL , Brown P , Pertwee RG , Huffman JW et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model . Nature 2000; 404: 84–87 .

Di Marzo V , Bifulco M , De Petrocellis L. Endocannabinoids and multiple sclerosis: a blessing from the ‘inner bliss’? Trends Pharmacol Sci 2000; 21: 195–197 .

Baker D , Pryce G , Croxford JL , Brown P , Pertwee RG , Makriyannis A et al. Endocannabinoids control spasticity in a multiple sclerosis model . FASEB J 2001; 15: 300–302 .

Eljaschewitsch E , Witting A , Mawrin C , Lee T , Schmidt PM , Wolf S et al. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells . Neuron 2006; 49: 4–7 .

Hemmer B , Cepok S , Nessler S , Sommer N. Pathogenesis of multiple sclerosis: an update on immunology . Curr Opin Neurol 2002; 1: 227–231 .

Malfitano AM , Matarese G , Bifulco M. From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases . Curr Drug Targets CNS Neurol Disord 2005; 4: 667–675 .

Brooks JW , Pryce G , Bisogno T , Jaggar SI , Hankey DJ , Brown P et al. Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic site of action different from the vanilloid VR1 and cannabinoid receptor CB(1) CB(2) receptors . Eur J Pharmacol 2002; 439: 83–92 .

Malfitano AM , Matarese G , Pisanti S , Grimaldi C , Laezza C , Bisogno T et al. Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis . J Neuroimmunol 2006;171: 110–119 .